The group's principle activities include identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and nervous system. The group's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase. The group operates from United States.
Executive Information
Name
Title
Email
Steven Elms
Chmn.
N/A
Barry Brand
Dir., CEO
N/A
Mark Baric
Dir., Pres.
N/A
Jim Free
COO - Management Team
N/A
Dan Burch
Exec. VP - Research, Development, Chief Medical Officer - Management Team
